Study of NMS-03305293 in Pts with Selected Advanced/Metastatic Solid Tumors

Summary

Phase I, first-in-human, open-label, multicenter, dose-escalation and dose expansion study with the aim of exploring safety, tolerability and preliminary antitumor activity of NMS-03305293 (a PARP inhibitor) as single agent in adult patients with selected advanced/metastatic, relapsed/refractory solid tumors who have exhausted standard treatment options or for whom standard therapy is considered unsuitable.

Timeline

Start

2019-11-25

Primary completion

2023-03-31

Completion

2024-05-16

Outcome

Outcome not reported

Stopped (Business): “The study closure is related to sponsor decision to shift towards the clinical development of NMS-03305293 in combination in a broader range of indication and not based on emerging safety or efficacy concerns.”

Drugs

Indications

No indication recorded.